SCINAI IMMUNOTHERAPEUTICS LT SCNI
ASignal's systematic analysis rates SCNI as Bearish.
Reflects the latest available analysis · analyzed Oct 11, 2026
The case on SCNI
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- High revenue growth (146.00% YoY)
- Strong growth score (0.9)
- Attractive valuation metrics (P/B 0.11x, P/S 1.07x)
- Low debt-to-equity ratio (0.31x)
- Positive cash position with $2.65M cash
- Negative operating and net margins (operating margin -466.52%, net margin -174.78%)
- Negative free cash flow ($-3.66M)
- Negative EV/EBITDA (-1.09x) indicating unprofitability
- Weak technical momentum (price below SMA20 and SMA50)
- No news coverage or Reddit mentions indicating low market sentiment
See the full verdict on SCNI
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes SCNI
Most investors never get a second opinion, let alone several. ASignal runs SCNI past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.